plerixafor (mozobil) Report issue

Small molecule Orphan Drug FDA Approved FDA First in Class Priority Review FDA

Active Ingredient History

  • Now
Plerixafor is a bicyclam molecule, which has been identified as a specific antagonist of CXCR4. It had originally been developed as an inhibitor of T-tropic human immunodeficiency virus, but later demonstrated to be an effective mobilizer of hematopoietic stem cells. Plerixafor was approved by FDA for autologous transplantation (in combination with granulocyte-colony stimulating factor) in patients with non-Hodgkin's lymphoma and multiple myeloma under the name Mozobil.   NCATS

  • Mol. Mass: 502.782
  • ALogP: 0.42
  • ChEMBL Molecule:
More Chemistry
  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)



United States

$6971.7960 - $9493.9920
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

1,1'-(1,4-phenylenebis-(methylene))-bis-1,4,8,11-tetraazacyclotetradecane octahydrochloride dihydrate | 1,1'-(1,4-phenylenebis(methylene))bis(1,4,8,11-tetraazacyclotetradecane)octahydrochloride dihydrate | amd3100 | amd 3100 | amd-3100 | amd 3329 | amd-3329 | bicyclam | gz316455 | jm3100 | jm 3100 | jm-3100 | mezobil | mozobil | perixafor | plerixafor | plerixafor hydrochloride | rpa bicyclam


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue